Condition or disease | Intervention/treatment | Phase |
---|---|---|
Recurrent B Acute Lymphoblastic Leukemia Recurrent B Lymphoblastic Lymphoma Refractory B Acute Lymphoblastic Leukemia Refractory B Lymphoblastic Lymphoma | Drug: Etoposide Drug: Doxorubicin Drug: Vincristine Drug: Prednisone Drug: Cyclophosphamide Biological: Inotuzumab Ozogamicin | Phase 1 |
This is a dose-escalation study of inotuzumab ozogamicin.
Patients receive etoposide, doxorubicin, and vincristine intravenously (IV) via continuous infusion on days 1-4, prednisone orally (PO) or IV twice daily (BID) on days 1-5, and cyclophosphamide IV over 1 hour on day 5. Patients also receive inotuzumab ozogamicin IV over 1 hour on days 8 and 15. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 30 days then annually for up to 5 years.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 24 participants |
Allocation: | Non-Randomized |
Intervention Model: | Sequential Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase I Study of Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin Plus Escalating Doses of Inotuzumab Ozogamicin (DA-EPOCH-InO) in Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia |
Actual Study Start Date : | September 24, 2019 |
Estimated Primary Completion Date : | February 28, 2024 |
Estimated Study Completion Date : | February 28, 2026 |
Arm | Intervention/treatment |
---|---|
Experimental: Dose -1 (0.3 mg/m^2)
Patients receive etoposide, doxorubicin, and vincristine IV via continuous infusion on days 1-4, prednisone PO or IV BID on days 1-5, and cyclophosphamide IV over 1 hour on day 5. Patients also receive inotuzumab ozogamicin IV over 1 hour on day 8. Treatment repeats approximately every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
|
Drug: Etoposide
Given IV
Other Names:
Drug: Doxorubicin Given IV
Other Names:
Drug: Vincristine Given IV
Other Names:
Drug: Prednisone Given PO or IV
Other Names:
Drug: Cyclophosphamide Given IV
Other Names:
Biological: Inotuzumab Ozogamicin Given IV
Other Names:
|
Experimental: Dose 1 (0.3 mg/m^2)
Dose 1 patients receive etoposide, doxorubicin, and vincristine IV via continuous infusion on days 1-4, prednisone PO or IV BID on days 1-5, and cyclophosphamide IV over 1 hour on day 5. Patients also receive inotuzumab ozogamicin IV over 1 hour on days 8 and 15. Treatment repeats approximately every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
|
Drug: Etoposide
Given IV
Other Names:
Drug: Doxorubicin Given IV
Other Names:
Drug: Vincristine Given IV
Other Names:
Drug: Prednisone Given PO or IV
Other Names:
Drug: Cyclophosphamide Given IV
Other Names:
Biological: Inotuzumab Ozogamicin Given IV
Other Names:
|
Experimental: Dose 2 (0.6 mg/m^2, 0.3 mg/m^2)
Dose 2 patients receive etoposide, doxorubicin, and vincristine IV via continuous infusion on days 1-4, prednisone PO or IV BID on days 1-5, and cyclophosphamide IV over 1 hour on day 5. Patients also receive inotuzumab ozogamicin IV over 1 hour on days 8 and 15. Treatment repeats approximately every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
|
Drug: Etoposide
Given IV
Other Names:
Drug: Doxorubicin Given IV
Other Names:
Drug: Vincristine Given IV
Other Names:
Drug: Prednisone Given PO or IV
Other Names:
Drug: Cyclophosphamide Given IV
Other Names:
Biological: Inotuzumab Ozogamicin Given IV
Other Names:
|
Experimental: Dose 3 (0.6 mg/m^2, 0.3 mg/m^2)
Dose 3 patients receive etoposide, doxorubicin, and vincristine IV via continuous infusion on days 1-4, prednisone PO or IV BID on days 1-5, and cyclophosphamide IV over 1 hour on day 5. Patients also receive inotuzumab ozogamicin IV over 1 hour on days 8 and 15. Treatment repeats approximately every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
|
Drug: Etoposide
Given IV
Other Names:
Drug: Doxorubicin Given IV
Other Names:
Drug: Vincristine Given IV
Other Names:
Drug: Prednisone Given PO or IV
Other Names:
Drug: Cyclophosphamide Given IV
Other Names:
Biological: Inotuzumab Ozogamicin Given IV
Other Names:
|
Will be defined as the highest dose of InO administered in which the incidence of dose limiting toxicities (DLTs) is < 33%, assuming at least 6 patients have been treated at this dose. DLTs assessed by:
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Relapsed or refractory disease, as defined by any of the following:
Recurrence of disease at any point after CR was achieved.
Detectable disease, as defined by any of the following:
Exclusion Criteria:
Except for management of circulating blasts noted above, adequate duration from prior therapy must be achieved before initiation of study treatment, as defined below:
Patients previously treated with InO will be eligible, unless they meet ANY of the following criteria:
Contact: Ryan Cassaday | 206-606-1202 | cassaday@seattlecc.org |
United States, Washington | |
Fred Hutch/University of Washington Cancer Consortium | Recruiting |
Seattle, Washington, United States, 98109 | |
Contact: Ryan Cassaday 206-606-1202 cassaday@seattlecc.org | |
Principal Investigator: Ryan Cassaday |
Principal Investigator: | Ryan Cassaday | Fred Hutch/University of Washington Cancer Consortium |
Tracking Information | |||||
---|---|---|---|---|---|
First Submitted Date ICMJE | June 17, 2019 | ||||
First Posted Date ICMJE | June 19, 2019 | ||||
Last Update Posted Date | May 18, 2021 | ||||
Actual Study Start Date ICMJE | September 24, 2019 | ||||
Estimated Primary Completion Date | February 28, 2024 (Final data collection date for primary outcome measure) | ||||
Current Primary Outcome Measures ICMJE |
Maximum tolerated dose (MTD) of inotuzumab ozogamicin (InO) [ Time Frame: Up to 5 years ] Will be defined as the highest dose of InO administered in which the incidence of dose limiting toxicities (DLTs) is < 33%, assuming at least 6 patients have been treated at this dose. DLTs assessed by:
|
||||
Original Primary Outcome Measures ICMJE |
Maximum tolerated dose (MTD) of inotuzumab ozogamicin (InO) [ Time Frame: Up to 5 years ] Will be defined as the highest dose of InO administered in which the incidence of dose limiting toxicities (DLTs) is < 33%, assuming at least 6 patients have been treated at this dose. DLTs assessed by:
|
||||
Change History | |||||
Current Secondary Outcome Measures ICMJE |
|
||||
Original Secondary Outcome Measures ICMJE | Same as current | ||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||
Descriptive Information | |||||
Brief Title ICMJE | Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia | ||||
Official Title ICMJE | A Phase I Study of Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin Plus Escalating Doses of Inotuzumab Ozogamicin (DA-EPOCH-InO) in Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia | ||||
Brief Summary | This phase I trial studies the best dose of inotuzumab ozogamicin in combination with chemotherapy in treating patients with B-cell acute lymphoblastic leukemia that has come back (recurrent) or that does not respond to treatment (refractory). Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a toxic agent called ozogamicin. Inotuzumab attaches to CD22 positive cancer cells in a targeted way and delivers ozogamicin to kill them. Drugs used in chemotherapy, such as etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving inotuzumab ozogamicin in combination with chemotherapy may kill more cancer cells than with chemotherapy alone in treating patients with recurrent or refractory B-cell acute lymphoblastic leukemia. | ||||
Detailed Description |
This is a dose-escalation study of inotuzumab ozogamicin. Patients receive etoposide, doxorubicin, and vincristine intravenously (IV) via continuous infusion on days 1-4, prednisone orally (PO) or IV twice daily (BID) on days 1-5, and cyclophosphamide IV over 1 hour on day 5. Patients also receive inotuzumab ozogamicin IV over 1 hour on days 8 and 15. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 30 days then annually for up to 5 years. |
||||
Study Type ICMJE | Interventional | ||||
Study Phase ICMJE | Phase 1 | ||||
Study Design ICMJE | Allocation: Non-Randomized Intervention Model: Sequential Assignment Masking: None (Open Label) Primary Purpose: Treatment |
||||
Condition ICMJE |
|
||||
Intervention ICMJE |
|
||||
Study Arms ICMJE |
|
||||
Publications * | Not Provided | ||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status ICMJE | Recruiting | ||||
Estimated Enrollment ICMJE |
24 | ||||
Original Estimated Enrollment ICMJE |
36 | ||||
Estimated Study Completion Date ICMJE | February 28, 2026 | ||||
Estimated Primary Completion Date | February 28, 2024 (Final data collection date for primary outcome measure) | ||||
Eligibility Criteria ICMJE |
Inclusion Criteria:
Exclusion Criteria:
|
||||
Sex/Gender ICMJE |
|
||||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | ||||
Accepts Healthy Volunteers ICMJE | No | ||||
Contacts ICMJE |
|
||||
Listed Location Countries ICMJE | United States | ||||
Removed Location Countries | |||||
Administrative Information | |||||
NCT Number ICMJE | NCT03991884 | ||||
Other Study ID Numbers ICMJE | RG1004854 NCI-2019-03811 ( Registry Identifier: NCI / CTRP ) 8786 ( Other Identifier: Fred Hutch/University of Washington Cancer Consortium ) P30CA015704 ( U.S. NIH Grant/Contract ) |
||||
Has Data Monitoring Committee | Yes | ||||
U.S. FDA-regulated Product |
|
||||
IPD Sharing Statement ICMJE |
|
||||
Responsible Party | University of Washington | ||||
Study Sponsor ICMJE | University of Washington | ||||
Collaborators ICMJE |
|
||||
Investigators ICMJE |
|
||||
PRS Account | University of Washington | ||||
Verification Date | May 2021 | ||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |